Boehringer Ingelheim And Sutro Biopharma Announced Successful Large-Scale Production Of Luvelta Using Sutro's Cell-Free Expression Technology For Ovarian Cancer Treatment; Achieved Industry Milestone With 4,500L GMP Batches Meeting Clinical Study...
Boehringer Ingelheim And Sutro Biopharma Announced Successful Large-Scale Production Of Luvelta Using Sutro's Cell-Free Expression Technology For Ovarian Cancer Treatment; Achieved Industry Milestone With 4,500L GMP Batches Meeting Clinical Study...
Boehringer Ingelheim And Sutro Biopharma Announced Successful Large-Scale Production Of Luvelta Using Sutro's Cell-Free Expression Technology For Ovarian Cancer Treatment; Achieved Industry Milestone With 4,500L GMP Batches Meeting Clinical Study Quality Standards
勃林格殷格翰與Sutro Biopharma宣佈成功大規模生產用於卵巢癌治療的Luvelta，採用Sutro的電芯無細胞表達科技；在達到臨牀研究質量標準的4,500L GMP批次中實現了行業里程碑
Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc.today announced that they successfully applied Sutro's proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro's Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FRα expressing cancers.
勃林格殷格翰BioXcellence和Sutro Biopharma Inc.今天宣佈，他們成功地將Sutro自主的電芯無細胞表達科技應用於商業規模，製造了luveltamab tazevibulin (luvelta)，這是Sutro的針對FRα的抗體藥物結合物（ADC），旨在治療廣泛的卵巢癌患者及其他FRα表達的癌症。
For the first time, the cross-functional teams were able to scale up Sutro's cell-free protein synthesis platform from a small-scale Good Manufacturing Practice (GMP) production to a large-scale GMP production marking an industry milestone. All batches of luvelta manufactured in 4,500 L at Boehringer's large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for the use in clinical studies.
這是跨職能團隊首次將Sutro的無細胞蛋白合成平台從小規模優良製造實踐（GMP）生產擴展到大規模GMP生產，標誌着行業里程碑。所有在奧地利維也納勃林格的大規模製造設施中生產的4,500 L的luvelta批次均符合臨牀研究所需的產品質量標準。
Sutro's cell free platform utilizes cellular components necessary for protein generation. The cell-free extract contains everything that is needed for synthesis, including energy production, transcription, and translation. By adding a specific DNA sequence, the desired protein can be synthesized. This technology has proven effective for a large range of molecule sizes, from small peptides to complex mammalian proteins such as monoclonal antibodies.
Sutro的無細胞平台利用了生成蛋白所需的細胞成分。無細胞提取物包含合成所需的一切，包括能源生產、轉錄和翻譯。通過添加特定的DNA序列，可以合成所需的蛋白。這項科技已被證明對從小肽到複雜的哺乳動物蛋白（如單克隆抗體）等大範圍分子規模都有效。
